Stock Price Quote

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE1624.10-111.15 (-6.41 %)
PREV CLOSE ( ) 1735.25
OPEN PRICE ( ) 1701.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9586
TODAY'S LOW / HIGH ( )1575.10 1758.40
52 WK LOW / HIGH ( )988.95 1909.55
NSE1626.60-109.2 (-6.29 %)
PREV CLOSE( ) 1735.80
OPEN PRICE ( ) 1739.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1626.60 (6175)
VOLUME 980746
TODAY'S LOW / HIGH( ) 1582.60 1760.90
52 WK LOW / HIGH ( )987.1 1910
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 2007
Management Info
Amit Indubhushan Bakshi - Chairman Amit Indubhushan Bakshi - Managing Director
Registered Office

Address Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, Bodakdev,
Ahmedabad,
Gujarat-380054

Phone 079 30451000 / 1001

Email eris@erislifesciences.com

Website www.eris.co.in

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

19May Eris Lifesciences informs about invest
Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligation..
13May Eris Lifesciences informs about board
Eris Lifesciences has informed that a Meeting of the Board of Directors..
13May Eris Lifesciences submits analyst meet
In accordance with the applicable requirements and regulations of the Se..
13May Eris Lifesciences informs about invest
Further to letter dated May 13, 2025, intimating about the date of the B..
21Mar Eris Lifesciences Informs about clarif
With refer to email bearing ref no. L/SURV/ONL/PV/ARJ/ 2024-2025/381 dat..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit304.7773.899999999998
Gross Profit 411.8 1200.5
Operating Profit 1377.25220.6
Net Sales 4047.716977.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  31529.10 (1.67%)
M.Cap ( in Cr)66997.14
Sanofi Cons. Health (BSE)
peergroup  5075.20 (2.17%)
M.Cap ( in Cr)11688.50
JB Chem & Pharma (BSE)
peergroup  1771.25 (5.98%)
M.Cap ( in Cr)27657.06
Divi's Lab (BSE)
peergroup  6589.85 (1.49%)
M.Cap ( in Cr)174939.81
Wockhardt (BSE)
peergroup  1730.65 (2.58%)
M.Cap ( in Cr)28120.56

Shareholding Pattern

PROMOTERS 54.85%
NON-INSTITUTION 18.66%
MUTUAL FUNDS/UTI 16.59%
FI/BANKS/INSURANCE 0.69%
GOVERNMENT 0%
FII 0%

About Eris Lifesciences Ltd.

Eris Lifesciences Ltd. was incorporated in the year 2007. Its today's share price is 1624.1. Its current market capitalisation stands at Rs 22119.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 15621.49 Cr and Total Income of Rs.15215.34 Cr. The company's management includes Rajeev Dalal, Prashant Gupta, Kalpana Unadkat, Sujesh Vasudevan, Kaushal Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan, Amit Indubhushan Bakshi, Amit Indubhushan Bakshi, Milind Talegaonkar.

It is listed on the BSE with a BSE Code of 540596 , NSE with an NSE Symbol of ERIS and ISIN of INE406M01024. It's Registered office is at Shivarth Ambit, Plot No. 142/2,Ramdas Road, Off S B R,Near Swati Bungalows, BodakdevAhmedabad-380054, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, RR Shah & Associate

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.